Key result
Disopyramide clearance shows no difference between patients with and without MI or HF.
Why the study?
Does the presence of myocardial infarction or congestive heart failure alter the pharmacokinetics of intravenous disopyramide?
Population
35 patients, comprising 24 with either congestive heart failure or acute myocardial infarction and 11…
Comparison
Disopyramide 150 mg bolus injection followed by… vs Patients without myocardial infarction or…
Design
Cohort
Follow-up
6 to 8 hours
Authors
Loading...
Supports unchanged disopyramide dosing in MI or HF; leaves open confirmation in prospective trials.
Does the presence of myocardial infarction or congestive heart failure alter the pharmacokinetics of intravenous disopyramide?
The pharmacokinetics of intravenous disopyramide are not significantly altered by the presence of acute myocardial infarction or congestive heart failure, suggesting the standard dosage regimen is satisfactory.
Bonde et al. (1985) studied Myocardial Infarction and Heart Failure (n=35). Disopyramide vs. Patients without myocardial infarction or heart failure was evaluated on Total body clearance of disopyramide (ml/min./kg). Disopyramide clearance in patients with myocardial infarction or heart failure was not significantly different from the 1.71 ml/min/kg observed in patients without these conditions.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: